Clinical efficacy of deep brain stimulation for psychiatric and neurological indications on a meta-analytic level.

IF 2.3 4区医学 Q2 PSYCHIATRY

International Journal of Psychiatry in Clinical Practice Pub Date : 2026-08-04 DOI:10.1080/13651501.2026.2710644

Victoria Froschauer, Johan Saelens, Anna Gramser, Julian Thewes, Marco Treven, Christof Brücke, Klaus Novak, Rupert Lanzenberger, Christoph Kraus

{"title":"Clinical efficacy of deep brain stimulation for psychiatric and neurological indications on a meta-analytic level.","authors":"Victoria Froschauer, Johan Saelens, Anna Gramser, Julian Thewes, Marco Treven, Christof Brücke, Klaus Novak, Rupert Lanzenberger, Christoph Kraus","doi":"10.1080/13651501.2026.2710644","DOIUrl":null,"url":null,"abstract":"Objective: Deep brain stimulation (DBS) is used to treat movement disorders, but it is rarely used for psychiatric indications. We aim to demonstrate clinical effects in randomised-controlled trials (RCTs) of DBS for clinically used neurological and psychiatric indications.Methods: We searched databases for RCTs conducting blinded comparisons of active to sham DBS for: obsessive-compulsive disorder (OCD), major depressive disorder (MDD), Gilles-de-la-Tourette syndrome (GTS), Parkinson's Disease (PD), essential tremor (ET), dystonia (DYT) and epilepsy (ED). We compared 28 studies with a meta-analytic approach of the indication-specific scores.Results: For psychiatric indications, we found a standardised mean difference (SMD) of -0.22 for MDD (p = .204), a SMD of -0.72 for OCD (p = .004) and a SMD of -1.22 for GTS (p = .014). For neurological indications, we found a SMD of 0.74 in PD (p < .001), a SMD of -1.42 in ET (p = .0003), a SMD of -0.71 for DYT (p = .006) and a SMD of -0.09 for ED (p = .790).Conclusions: Effect sizes in clinical trials were highest in ET in neurology and in GTS in psychiatry. These results underscore that wider clinical use in the psychiatric indications OCD and GTS is justifiable.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"1-14"},"PeriodicalIF":2.3000,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Psychiatry in Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13651501.2026.2710644","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Deep brain stimulation (DBS) is used to treat movement disorders, but it is rarely used for psychiatric indications. We aim to demonstrate clinical effects in randomised-controlled trials (RCTs) of DBS for clinically used neurological and psychiatric indications.

Methods: We searched databases for RCTs conducting blinded comparisons of active to sham DBS for: obsessive-compulsive disorder (OCD), major depressive disorder (MDD), Gilles-de-la-Tourette syndrome (GTS), Parkinson's Disease (PD), essential tremor (ET), dystonia (DYT) and epilepsy (ED). We compared 28 studies with a meta-analytic approach of the indication-specific scores.

Results: For psychiatric indications, we found a standardised mean difference (SMD) of -0.22 for MDD (p = .204), a SMD of -0.72 for OCD (p = .004) and a SMD of -1.22 for GTS (p = .014). For neurological indications, we found a SMD of 0.74 in PD (p < .001), a SMD of -1.42 in ET (p = .0003), a SMD of -0.71 for DYT (p = .006) and a SMD of -0.09 for ED (p = .790).

Conclusions: Effect sizes in clinical trials were highest in ET in neurology and in GTS in psychiatry. These results underscore that wider clinical use in the psychiatric indications OCD and GTS is justifiable.

查看原文本刊更多论文

脑深部刺激治疗精神病学和神经学适应症的临床疗效：meta分析水平。

目的：脑深部电刺激（DBS）用于治疗运动障碍，但很少用于精神疾病适应症。我们的目标是在随机对照试验（rct）中证明DBS用于临床使用的神经和精神适应症的临床效果。方法：我们检索数据库，对强迫症（OCD）、重度抑郁症（MDD）、Gilles-de-la-Tourette综合征（GTS）、帕金森氏病（PD）、特发性震颤（ET）、肌张力障碍（DYT）和癫痫（ED）进行主动DBS与假性DBS的随机对照试验进行盲法比较。我们比较了28项研究的适应症特异性评分的荟萃分析方法。结果：对于精神适应症，我们发现MDD的标准化平均差异（SMD）为-0.22 (p = .204)，强迫症的标准化平均差异（SMD）为-0.72 (p = .004)， GTS的标准化平均差异（SMD）为-1.22 （p = .014）。对于神经学适应症，我们发现PD的SMD为0.74 (p = 0.0003)， DYT的SMD为-0.71 (p = 0.006)， ED的SMD为-0.09 （p = 0.790）。结论：在临床试验中，神经病学的ET和精神病学的GTS的效应量最高。这些结果强调了在精神病适应症OCD和GTS中更广泛的临床应用是合理的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Psychiatry in Clinical Practice 医学-精神病学

CiteScore

6.00

自引率

3.30%

发文量

审稿时长

>12 weeks

期刊介绍： International Journal of Psychiatry in Clinical Practice provides an international forum for communication among health professionals with clinical, academic and research interests in psychiatry. The journal gives particular emphasis to papers that integrate the findings of academic research into realities of clinical practice. Focus on the practical aspects of managing and treating patients. Essential reading for the busy psychiatrist, trainee and interested physician. Includes original research papers, comprehensive review articles and short communications. Key words: Psychiatry, Neuropsychopharmacology, Mental health, Neuropsychiatry, Clinical Neurophysiology, Psychophysiology, Psychotherapy, Addiction, Schizophrenia, Depression, Bipolar Disorders and Anxiety.